Wednesday, February 22, 4:42 PM
An FDA advisory panel votes 20-2 in favor of recommending Vivus (VVUS) weight-loss drug Qnexa. Shares still halted. (earlier)
This Market Current was sent to 2,601 people who get email alerts on VVUS.
Sequel study was worth the wait. Now it's time to focus on the full report to determine if the FDA will rule in line with the Ad Comm. This is a big short term win for VVUS; too bad it wasn't 22-0 though.
This news story has 1 comment: